5108s10128
NM_001315507.1 NM_001315508.1 NM_006197.3 XM_006716336.3 XM_006716340.3 XM_006716349.3 XM_011544528.2 XM_011544529.2 XM_011544530.2 XM_011544532.2 XM_011544533.2 XM_011544534.2 XM_011544535.2 XM_011544540.2 XM_017013472.1 XM_017013473.1 XM_017013474.1 XM_017013475.1 XM_017013476.1 XM_017013477.1 XM_017013478.1 XM_017013479.1 XM_017013480.1 XM_017013481.1 XM_017013482.1 XM_017013483.1 XM_017013484.1 XM_017013485.1 XM_017013486.1 XM_017013487.1 XM_017013488.1 XM_017013489.1 XM_017013490.1 XM_017013491.1 XM_017013492.1 XM_017013493.1 XM_017013494.1 XM_017013495.1 XM_017013496.1 XM_017013497.1 XM_017013498.1 XM_017013499.1 XM_017013500.1 XM_017013501.1 XM_017013502.1 XM_017013503.1 XM_017013504.1 XM_017013505.1 XM_017013506.1 XM_017013507.1 XM_017013508.1
18%(+/-2% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00196390_m1]
HeLa cells were reverse transfected with 5nM gene-specific Silencer® Select siRNA or 5nM Silencer® Select Negative Control #2 siRNA. 48 hours post-transfection, gene expression analysis was performed using the TaqMan® Gene Expression Cells-to-CT Kit and appropriate TaqMan® Gene Expression Assays. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.